^
    Back
    Association details:
    Biomarker:BCR-ABL1 fusion
    Cancer:Acute Lymphocytic Leukemia
    Drug:Bosulif (bosutinib) (Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    INDUCTION REGIMENS FOR Ph-POSITIVE ALL: Other Recommended regimens…TKI + vincristine + dexamethasone…TKI options include (in alphabetical order): bosutinib, dasatinib, imanitib, nilotinib or ponatinib.
    Secondary therapy:
    vincristine + dexamethasone
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Chronic Myeloid Leukemia)
    New
    Excerpt:
    BOSULIF is a kinase inhibitor indicated for the treatment of...pediatric patients 1 year of age and older with chronic phase Ph+ (≥20%) in adult and pediatric patients are creatinine increased, hemoglobin chronic myelogenous leukemia (CML), newly-diagnosed or resistant or decreased, lymphocyte count decreased, platelets decreased, ALT intolerant to prior therapy.